The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Chemotherapy, Adjuvant

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Chemotherapy, Adjuvant


Psychiatry related information on Chemotherapy, Adjuvant


High impact information on Chemotherapy, Adjuvant


Chemical compound and disease context of Chemotherapy, Adjuvant


Biological context of Chemotherapy, Adjuvant


Anatomical context of Chemotherapy, Adjuvant


Associations of Chemotherapy, Adjuvant with chemical compounds


Gene context of Chemotherapy, Adjuvant


Analytical, diagnostic and therapeutic context of Chemotherapy, Adjuvant


  1. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. Muss, H.B., Thor, A.D., Berry, D.A., Kute, T., Liu, E.T., Koerner, F., Cirrincione, C.T., Budman, D.R., Wood, W.C., Barcos, M. N. Engl. J. Med. (1994) [Pubmed]
  2. Resolution of Helicobacter pylori-associated gastric lymphoproliferative disease in a child. Blecker, U., McKeithan, T.W., Hart, J., Kirschner, B.S. Gastroenterology (1995) [Pubmed]
  3. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. Edler, D., Glimelius, B., Hallström, M., Jakobsen, A., Johnston, P.G., Magnusson, I., Ragnhammar, P., Blomgren, H. J. Clin. Oncol. (2002) [Pubmed]
  4. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. O'Connell, M.J., Laurie, J.A., Kahn, M., Fitzgibbons, R.J., Erlichman, C., Shepherd, L., Moertel, C.G., Kocha, W.I., Pazdur, R., Wieand, H.S., Rubin, J., Vukov, A.M., Donohue, J.H., Krook, J.E., Figueredo, A. J. Clin. Oncol. (1998) [Pubmed]
  5. Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. Nakajima, T., Takahashi, T., Takagi, K., Kuno, K., Kajitani, T. J. Clin. Oncol. (1984) [Pubmed]
  6. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Bouché, O., Ychou, M., Burtin, P., Bedenne, L., Ducreux, M., Lebreton, G., Baulieux, J., Nordlinger, B., Martin, C., Seitz, J.F., Tigaud, J.M., Echinard, E., Stremsdoerfer, N., Milan, C., Rougier, P. Ann. Oncol. (2005) [Pubmed]
  7. Fatigue, weight gain, lethargy and amenorrhea in breast cancer patients on chemotherapy: is subclinical hypothyroidism the culprit? Kumar, N., Allen, K.A., Riccardi, D., Bercu, B.B., Cantor, A., Minton, S., Balducci, L., Jacobsen, P.B. Breast Cancer Res. Treat. (2004) [Pubmed]
  8. Measurement of 5-fluorouracil in scalp hair: a possible index of patient compliance with oral adjuvant chemotherapy. Uematsu, T., Nakashima, M., Fujii, M., Hamano, K., Yasutomi, M., Kodaira, S., Kato, T., Kotake, K., Oka, H., Masuike, T. Eur. J. Clin. Pharmacol. (1996) [Pubmed]
  9. Adjuvant chemotherapy of breast cancer--the Consensus Development Conference revisited. Abeloff, M.D., Beveridge, R.A. Oncology (Williston Park, N.Y.) (1988) [Pubmed]
  10. Leukemia after adjuvant chemotherapy with semustine (methyl-CCNU)--evidence of a dose-response effect. Boice, J.D., Greene, M.H., Killen, J.Y., Ellenberg, S.S., Fraumeni, J.F., Keehn, R.J., McFadden, E., Chen, T.T., Stablein, D. N. Engl. J. Med. (1986) [Pubmed]
  11. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. Jänicke, F., Prechtl, A., Thomssen, C., Harbeck, N., Meisner, C., Untch, M., Sweep, C.G., Selbmann, H.K., Graeff, H., Schmitt, M. J. Natl. Cancer Inst. (2001) [Pubmed]
  12. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. Paik, S., Bryant, J., Tan-Chiu, E., Yothers, G., Park, C., Wickerham, D.L., Wolmark, N. J. Natl. Cancer Inst. (2000) [Pubmed]
  13. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes. Shapiro, C.L., Gelman, R.S., Hayes, D.F., Osteen, R., Obando, A., Canellos, G.P., Frei, E., Henderson, I.C. J. Natl. Cancer Inst. (1993) [Pubmed]
  14. Repeated adjuvant chemotherapy with phenylalanine mustard or 5-fluorouracil, cyclophosphamide, and prednisone with or without radiation, after mastectomy for breast cancer. Ahmann, D.L., Scanlon, P.W., Bisel, H.F., Edmonson, J.H., Frytak, S., Payne, W.S., O'Fallon, J.R., Hahn, R.G., Ingle, J.N., O'Connell, M.J., Rubin, J. Lancet (1978) [Pubmed]
  15. Doxorubicin and cisplatin with granulocyte colony-stimulating factor as adjuvant chemotherapy for osteosarcoma: phase II trial of the European Osteosarcoma Intergroup. Ornadel, D., Souhami, R.L., Whelan, J., Nooy, M., Ruiz de Elvira, C., Pringle, J., Lewis, I., Steward, W.P., George, R., Bridgewater, J. J. Clin. Oncol. (1994) [Pubmed]
  16. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. Meinardi, M.T., van Veldhuisen, D.J., Gietema, J.A., Dolsma, W.V., Boomsma, F., van den Berg, M.P., Volkers, C., Haaksma, J., de Vries, E.G., Sleijfer, D.T., van der Graaf, W.T. J. Clin. Oncol. (2001) [Pubmed]
  17. Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer. Grau, J.J., Estapé, J., Fuster, J., Filella, X., Visa, J., Terés, J., Soler, G., Albiol, S., García-Valdecasas, J.C., Grande, L., Bombí, J., Bordas, J., Alcobendas, F. J. Clin. Oncol. (1998) [Pubmed]
  18. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. Toikkanen, S., Helin, H., Isola, J., Joensuu, H. J. Clin. Oncol. (1992) [Pubmed]
  19. Rational selection of adjuvant chemotherapy after cytoreduction surgery for murine neuroblastoma. Naito, H., Ziegler, M.M., Tsou, K.C. Cancer Res. (1985) [Pubmed]
  20. Genetic alterations in ERBB2-amplified breast carcinomas. Isola, J., Chu, L., DeVries, S., Matsumura, K., Chew, K., Ljung, B.M., Waldman, F.M. Clin. Cancer Res. (1999) [Pubmed]
  21. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Tsuji, T., Hidaka, S., Sawai, T., Nakagoe, T., Yano, H., Haseba, M., Komatsu, H., Shindou, H., Fukuoka, H., Yoshinaga, M., Shibasaki, S., Nanashima, A., Yamaguchi, H., Yasutake, T., Tagawa, Y. Clin. Cancer Res. (2003) [Pubmed]
  22. Antiproliferative activity of melatonin by transcriptional inhibition of cyclin D1 expression: a molecular basis for melatonin-induced oncostatic effects. Cini, G., Neri, B., Pacini, A., Cesati, V., Sassoli, C., Quattrone, S., D'Apolito, M., Fazio, A., Scapagnini, G., Provenzani, A., Quattrone, A. J. Pineal Res. (2005) [Pubmed]
  23. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. Kondagunta, G.V., Sheinfeld, J., Mazumdar, M., Mariani, T.V., Bajorin, D., Bacik, J., Bosl, G.J., Motzer, R.J. J. Clin. Oncol. (2004) [Pubmed]
  24. Granulocyte-macrophage colony-stimulating factor treatment before doxorubicin and cyclophosphamide chemotherapy priming in women with early-stage breast cancer. Kobrinsky, N.L., Sjolander, D.E., Cheang, M.S., Levitt, R., Steen, P.D. J. Clin. Oncol. (1999) [Pubmed]
  25. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Jordan, V.C., Fritz, N.F., Tormey, D.C. Cancer Res. (1987) [Pubmed]
  26. Radiation-related pericardial effusions in patients with Hodgkin's disease. Ruckdeschel, J.C., Chang, P., Martin, R.G., Byhardt, R.W., O'Connell, M.J., Sutherland, J.C., Wiernik, P.H. Medicine (Baltimore) (1975) [Pubmed]
  27. Adjuvant therapy of testis cancer: the role of vinblastine and bleomycin. Samuels, M.L., Johnson, D.E. J. Urol. (1980) [Pubmed]
  28. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Elsaleh, H., Joseph, D., Grieu, F., Zeps, N., Spry, N., Iacopetta, B. Lancet (2000) [Pubmed]
  29. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Francini, G., Petrioli, R., Lorenzini, L., Mancini, S., Armenio, S., Tanzini, G., Marsili, S., Aquino, A., Marzocca, G., Civitelli, S. Gastroenterology (1994) [Pubmed]
  30. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Rose, D.P., Davis, T.E. Lancet (1977) [Pubmed]
  31. Pretreatment serum lactate dehydrogenase predicting metastatic spread in Ewing's sarcoma. Brereton, H.D., Simon, R., Pomeroy, T.C. Ann. Intern. Med. (1975) [Pubmed]
  32. Accelerated concomitant boost radiotherapy and chemotherapy for advanced nasopharyngeal carcinoma. Wolden, S.L., Zelefsky, M.J., Kraus, D.H., Rosenzweig, K.E., Chong, L.M., Shaha, A.R., Zhang, H., Harrison, L.B., Shah, J.P., Pfister, D.G. J. Clin. Oncol. (2001) [Pubmed]
  33. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. Berry, D.A., Muss, H.B., Thor, A.D., Dressler, L., Liu, E.T., Broadwater, G., Budman, D.R., Henderson, I.C., Barcos, M., Hayes, D., Norton, L. J. Clin. Oncol. (2000) [Pubmed]
  34. Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases. Nagasaka, T., Sharp, G.B., Notohara, K., Kambara, T., Sasamoto, H., Isozaki, H., MacPhee, D.G., Jass, J.R., Tanaka, N., Matsubara, N. Clin. Cancer Res. (2003) [Pubmed]
  35. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Chappuis, P.O., Donato, E., Goffin, J.R., Wong, N., Bégin, L.R., Kapusta, L.R., Brunet, J.S., Porter, P., Foulkes, W.D. Ann. Oncol. (2005) [Pubmed]
  36. Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. Moureau-Zabotto, L., Ricci, S., Lefranc, J.P., Coulet, F., Genestie, C., Antoine, M., Uzan, S., Lotz, J.P., Touboul, E., Lacave, R. Br. J. Cancer (2006) [Pubmed]
  37. Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer. Bleeker, W.A., Hayes, V.M., Karrenbeld, A., Hofstra, R.M., Verlind, E., Hermans, J., Poppema, S., Buys, C.H., Plukker, J.T. Dis. Colon Rectum (2001) [Pubmed]
  38. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. Mansour, E.G., Gray, R., Shatila, A.H., Osborne, C.K., Tormey, D.C., Gilchrist, K.W., Cooper, M.R., Falkson, G. N. Engl. J. Med. (1989) [Pubmed]
  39. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Nakazato, H., Koike, A., Saji, S., Ogawa, N., Sakamoto, J. Lancet (1994) [Pubmed]
  40. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. Hamada, C., Tanaka, F., Ohta, M., Fujimura, S., Kodama, K., Imaizumi, M., Wada, H. J. Clin. Oncol. (2005) [Pubmed]
WikiGenes - Universities